79 studies found for:    Alzheimer's disease | United States, Tennessee
Show Display Options
Rank Status Study
1 Unknown  Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)
Condition: Alzheimer Disease
Interventions: Drug: alphatocopherol;   Drug: Selenium;   Drug: Placebo replacement for vitamin E;   Drug: Placebo replacement for Selenium
2 Terminated A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Drug: Bapineuzumab
3 Recruiting 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Aducanumab (BIIB037);   Drug: Placebo
4 Completed Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)
Condition: Alzheimer's Disease
Interventions: Drug: Bapineuzumab 0.5 mg/kg;   Drug: Placebo Control;   Drug: Bapineuzumab 1.0 m/kg
5 Completed Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)
Condition: Alzheimer's Disease
Interventions: Drug: Bapineuzumab 0.5 mg/kg;   Drug: Placebo Control;   Drug: Bapineuzumab 1.0 m/kg
6 Recruiting Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Azeliragon;   Drug: Placebo
7 Completed
Has Results
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Dimebon;   Drug: Placebo
8 Completed Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's
Conditions: Alzheimer Disease;   Dementia
Intervention: Drug: MPC-7869
9 Recruiting Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)
Conditions: Amnestic Mild Cognitive Impairment;   Alzheimer's Disease;   Prodromal Alzheimer's Disease
Interventions: Drug: Verubecestat (Part I and Part II);   Drug: Placebo (Part I);   Drug: Verubecestat (Part II)
10 Completed Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: TRx0237 200 mg/day;   Drug: Placebo
11 Enrolling by invitation Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)
Conditions: Alzheimer's Disease;   Behavioral Variant Frontotemporal Dementia
Intervention: Drug: TRx0237
12 Completed Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Drug: Rosiglitazone
13 Active, not recruiting AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
Condition: Alzheimer's Disease
Interventions: Drug: AC-1204;   Drug: Placebo
14 Active, not recruiting Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Condition: Alzheimer's Disease
Interventions: Drug: Solanezumab;   Drug: Placebo
15 Terminated A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Drug: FK962
16 Terminated
Has Results
An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Drug: Dimebon
17 Completed
Has Results
Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline
Condition: Alzheimer Disease
Interventions: Drug: Rivastigmine 5 cm^2;   Drug: Rivastigmine 10 cm^2;   Drug: Rivastigmine 15 cm^2;   Drug: Placebo to 15 cm^2 patch;   Drug: Placebo to 10 cm^2 patch
18 Completed
Has Results
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44
Condition: Alzheimer's Disease
Interventions: Drug: Rivastigmine 4.6 mg/24 h (5 cm^2);   Drug: Rivastigmine 9.5 mg/24 h (10 cm^2);   Drug: Rivastigmine 13.3 mg/24 h (15 cm^2);   Drug: Placebo
19 Completed 18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
Condition: Alzheimer Disease
Intervention: Drug: xaliproden (SR57746A)
20 Recruiting Long Term, Extension Study of the Safety and Efficacy of AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Condition: Agitation in Alzheimer's Disease
Intervention: Drug: AVP-786

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years